Johnson & Johnson to acquire Alios BioPharma
Johnson & Johnson plans to buy Alios BioPharma Inc., a clinical-stage biopharmaceutical company focused on developing therapies for viral diseases, for $1.75 billion in cash. J&J said Tuesday that the acquisition will bolster its current pipeline for viral diseases.